AbbVie Inc.
NYSE:ABBVDrug Manufacturers - General
-$4.65 today
- Market cap
- $505.47B
- Beta
- 0.31
- P/E (TTM)
- 105.6
- EPS (TTM)
- $2.05
- Dividend yield
- 3.11%
Volume 4.73M
Average 6.47M
ABBV Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
AbbVie Inc.NYSE: ABBV
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures grows, but more slowly than its trailing trend
Q2 FY2026 capital expenditures of $322M (cash outflow) rose 19.7% year over year, behind the +24.2% change in trailing-twelve-month capital expenditures. Sequentially, it rose 21.5% from the prior quarter. Over 3 fiscal years it compounded at +20.4% a year.
Context
- Capital expenditures amounted to 2.0% of revenue in FY2025, up 0.3 pp from a year earlier.
- Capital expenditures grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +19.7% toward the trailing-twelve-month pace of +24.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (1.21B) USD
- Year-over-year change
- -24.6%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.21B) | -24.6% |
| FY2024 | 2024-12-31 | (974M) | -25.4% |
| FY2023 | 2023-12-31 | (777M) | -11.8% |
| FY2022 | 2022-12-31 | (695M) | +11.7% |
| FY2021 | 2021-12-31 | (787M) | — |
Capital Expenditures vs competitors
How ABBV compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +24.2% is the 2nd highest of 10, against a peer median of -12.1%.
- Capital expenditures amounts to 2.0% of revenue for ABBV, versus a peer median of 5.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $8.03B USD | -26.9% | +38.0% | 10.1% | |
| LTM Sep 2026 | $5.57B USD | +8.6% | +6.4% | 5.6% | |
| LTM Sep 2026 | $4.01B USD | -28.0% | +31.9% | 6.5% | |
| LTM Jun 2026 | $3.9B USD | +2.4% | -2.1% | 5.9% | |
| LTM Jun 2026 | $2.57B USD | -35.5% | -11.4% | 4.6% | |
| LTM Jun 2026 | $2.42B USD | -12.1% | -6.7% | 3.8% | |
| LTM Jun 2026 | $2.3B USD | +63.6% | +25.7% | 6.0% | |
| LTM Jun 2026 | £1.76B GBP | -42.4% | -2.2% | 5.3% | |
| LTM Jun 2026 | $1.34B USD | +1.4% | +5.5% | 2.7% | |
| LTM Jun 2026 | $1.3B USD | +24.2% | +20.4% | 2.0% | |
| Peer median (excluding ABBV) | — | -12.1% | +5.5% | 5.6% | |
Competitors are the stored peer set for ABBV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 11.55B | 11.85B | 4.82B | 4.29B | 4.23B |
| Depreciation & Amortization | 8.52B | 8.47B | 8.7B | 8.39B | 8.14B |
| Deferred Income Tax | (898M) | (1.93B) | (2.89B) | (1.45B) | (492M) |
| Stock-Based Compensation | 692M | 671M | 747M | 911M | 955M |
| Change in Working Capital | (1.32B) | (258M) | 2.81B | (2.78B) | (2.36B) |
| Accounts Receivables | (1.32B) | (1.46B) | 66M | 207M | (1.49B) |
| Inventory | (142M) | (686M) | (417M) | (319M) | (234M) |
| Accounts Payables | 1.63B | 1.61B | 3.84B | 177M | 951M |
| Other Working Capital | (1.49B) | 278M | (676M) | (2.85B) | (1.59B) |
| Other Non-Cash Items | 4.24B | 6.15B | 8.65B | 9.45B | 8.6B |
| Operating Cash Flow | 22.78B | 24.94B | 22.84B | 18.81B | 19.03B |
| Capital Expenditures | (787M) | (695M) | (777M) | (974M) | (1.21B) |
| Acquisitions (Net) | (1.9B) | (794M) | (1.22B) | (17.49B) | (204M) |
| Purchases of Investments | (119M) | (1.44B) | (77M) | (73M) | (35M) |
| Sales of Investments | 98M | 1.53B | 55M | 555M | 76M |
| Other Investing Activities | 366M | 774M | 13M | (2.84B) | (5.27B) |
| Investing Cash Flow | (2.34B) | (623M) | (2.01B) | (20.82B) | (6.64B) |
| Debt Repayment | (8.41B) | (12.43B) | (4.15B) | 7.35B | (327M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 172M |
| Common Stock Repurchased | (934M) | (1.49B) | (1.97B) | (1.71B) | (980M) |
| Dividends Paid | (9.26B) | (10.04B) | (10.54B) | (11.03B) | (11.66B) |
| Other Financing Activities | (430M) | (840M) | (562M) | 172M | 68M |
| Financing Cash Flow | (19.04B) | (24.8B) | (17.22B) | (5.21B) | (12.72B) |
| Effect of Forex Changes | (97M) | (62M) | 5M | (65M) | 42M |
| Net Change in Cash | 1.3B | (545M) | 3.61B | (7.29B) | (295M) |
| Free Cash Flow | 21.99B | 24.25B | 22.06B | 17.83B | 17.82B |
AbbVie Inc.
NYSE:ABBV
Intrinsic Alpha fair value
Locked
Current Price
$285.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.